These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34940840)

  • 1. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response.
    Christiansen SN; Ørnbjerg LM; Rasmussen SH; Loft AG; Askling J; Iannone F; Zavada J; Michelsen B; Nissen M; Onen F; Santos MJ; Pombo-Suarez M; Relas H; Macfarlane GJ; Tomsic M; Codreanu C; Gudbjornsson B; Van der Horst-Bruinsma I; Di Giuseppe D; Glintborg B; Gremese E; Pavelka K; Kristianslund EK; Ciurea A; Akkoc N; Barcelos A; Sánchez-Piedra C; Peltomaa R; Jones GT; Rotar Z; Ionescu R; Grondal G; Van de Sande MGH; Laas K; Østergaard M; Hetland ML
    Rheumatology (Oxford); 2022 Aug; 61(9):3799-3807. PubMed ID: 34940840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis.
    Michelsen B; Ørnbjerg LM; Kvien TK; Pavelka K; Nissen MJ; Nordström D; Santos MJ; Koca SS; Askling J; Rotar Z; Gudbjornsson B; Codreanu C; Loft AG; Kristianslund EK; Mann HF; Ciurea A; Eklund KK; Vieira-Sousa E; Yazici A; Jacobsson L; Tomšič M; Löve TJ; Ionescu R; van der Horst-Bruinsma IE; Iannone F; Pombo-Suarez M; Jones GT; Hyldstrup LH; Krogh NS; Hetland ML; Østergaard M
    Rheumatology (Oxford); 2020 Sep; 59(9):2455-2461. PubMed ID: 31960053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
    Ørnbjerg LM; Brahe CH; Askling J; Ciurea A; Mann H; Onen F; Kristianslund EK; Nordström D; Santos MJ; Codreanu C; Gómez-Reino J; Rotar Z; Gudbjornsson B; Di Giuseppe D; Nissen MJ; Pavelka K; Birlik M; Kvien T; Eklund KK; Barcelos A; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Loft AG; van der Horst-Bruinsma I; Jones G; Iannone F; Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
    Ann Rheum Dis; 2019 Nov; 78(11):1536-1544. PubMed ID: 31431486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
    Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
    Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
    Brahe CH; Ørnbjerg LM; Jacobsson L; Nissen MJ; Kristianslund EK; Mann H; Santos MJ; Reino JG; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Pavelka K; Barcelos A; Sánchez-Piedra C; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; van der Horst-Bruinsma IE; Macfarlane GJ; Iannone F; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML
    Rheumatology (Oxford); 2020 Jul; 59(7):1640-1650. PubMed ID: 31665497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.
    Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Lindström U; Pavelka K; Yilmaz N; Favalli EG; Nissen MJ; Michelsen B; Vieira-Sousa E; Jones GT; Ionescu R; Relas H; Sanchez-Piedra C; Tomšič M; Geirsson AJ; van der Horst-Bruinsma I; Askling J; Loft AG; Nekvindova L; Direskeneli H; Iannone F; Ciurea A; Fagerli KM; Santos MJ; Macfarlane GJ; Codreanu C; Eklund K; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Rusman T; Østergaard M; Hetland ML
    J Rheumatol; 2023 Aug; 50(8):1009-1019. PubMed ID: 36455943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network.
    Hellamand P; van de Sande MGH; Ørnbjerg LM; Klausch T; Eklund KK; Relas H; Santos MJ; Vieira-Sousa E; Loft AG; Glintborg B; Østergaard M; Lindström U; Wallman JK; Michelsen B; Fagerli KM; Castrejón I; Gudbjornsson B; Love TJ; Vencovský J; Nekvindová L; Rotar Ž; Tomšič M; Díaz-González F; Kenar G; Tuğsal HY; Iannone F; Ramonda R; Codreanu C; Mogosan C; Nissen MJ; Möller B; Hetland ML; van der Horst-Bruinsma IE
    Arthritis Rheumatol; 2024 Apr; 76(4):587-598. PubMed ID: 37975166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
    Nissen M; Delcoigne B; Di Giuseppe D; Jacobsson L; Hetland ML; Ciurea A; Nekvindova L; Iannone F; Akkoc N; Sokka-Isler T; Fagerli KM; Santos MJ; Codreanu C; Pombo-Suarez M; Rotar Z; Gudbjornsson B; van der Horst-Bruinsma I; Loft AG; Möller B; Mann H; Conti F; Yildirim Cetin G; Relas H; Michelsen B; Avila Ribeiro P; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Askling J; Glintborg B; Lindström U
    Rheumatology (Oxford); 2022 Nov; 61(12):4741-4751. PubMed ID: 35323903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.
    Christiansen SN; Horskjær Rasmussen S; Pons M; Michelsen B; Glintborg B; Gudbjornsson B; Grondal G; Vencovsky J; Loft AG; Rotar Z; Pirkmajer KP; Nissen MJ; Baranová J; Macfarlane GJ; Jones GT; Iannone F; Caporali R; Laas K; Vorobjov S; Giuseppe DD; Olofsson T; Provan SA; Fagerli KM; Castrejon I; Otero-Varela L; van de Sande M; van der Horst-Bruinsma I; Nordström D; Kuusalo L; Bernardes M; Hetland ML; Østergaard M; Midtbøll Ørnbjerg L
    Semin Arthritis Rheum; 2024 Apr; 65():152388. PubMed ID: 38301349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial.
    Michielsens CAJ; Boers N; den Broeder N; Wenink MH; van der Maas A; Mahler EAM; Mulder MLM; van der Heijde D; van den Hoogen FHJ; Verhoef LM; den Broeder AA
    Trials; 2020 Jan; 21(1):90. PubMed ID: 31941544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.
    Flouri I; Goutakoli P; Repa A; Bertsias A; Avgoustidis N; Eskitzis A; Pitsigavdaki S; Kalogiannaki E; Terizaki M; Bertsias G; Sidiropoulos P
    Rheumatol Int; 2024 Feb; 44(2):249-261. PubMed ID: 37815625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial.
    Michielsens CA; den Broeder N; van den Hoogen FH; Mahler EA; Teerenstra S; van der Heijde D; Verhoef LM; den Broeder AA
    Ann Rheum Dis; 2022 Oct; 81(10):1392-1399. PubMed ID: 35701155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
    Feist E; Baraliakos X; Behrens F; Thaçi D; Plenske A; Klaus P; Meng T
    Rheumatol Ther; 2024 Apr; 11(2):331-348. PubMed ID: 38308727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care.
    Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Jacobsson L; Loft AG; Iannone F; Fagerli KM; Vencovsky J; Santos MJ; Möller B; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Cefle A; Eklund K; Codreanu C; Jones G; van der Sande M; Wallman JK; Sebastiani M; Michelsen B; Závada J; Nissen MJ; Sanchez-Piedra C; Tomšič M; Love TJ; Relas H; Mogosan C; Hetland ML; Østergaard M
    J Rheumatol; 2024 Apr; 51(4):378-389. PubMed ID: 38224992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries.
    Linde L; Ørnbjerg LM; Georgiadis S; H Rasmussen S; Lindström U; Askling J; Michelsen B; Di Giuseppe D; Wallman JK; Gudbjornsson B; Love TJ; Nordström DC; Yli-Kerttula T; Nekvindová L; Vencovský J; Iannone F; Cauli A; Loft AG; Glintborg B; Laas K; Rotar Z; Tomšič M; Macfarlane GJ; Möller B; van de Sande M; Codreanu C; Nissen MJ; Birlik M; Erten S; Santos MJ; Vieira-Sousa E; Hetland ML; Østergaard M
    Rheumatology (Oxford); 2024 Mar; 63(3):751-764. PubMed ID: 37314967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.
    Fornaro M; Righetti G; Abbruzzese A; Lopalco G; Cacciapaglia F; Anelli MG; Venerito V; Iannone F
    Clin Rheumatol; 2021 Sep; 40(9):3659-3665. PubMed ID: 33864158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.
    Mease PJ; Karki C; Liu M; Li Y; Gershenson B; Feng H; Hur P; Greenberg JD
    RMD Open; 2019; 5(1):e000880. PubMed ID: 31168408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study.
    Currado D; Saracino F; Ruscitti P; Marino A; Pantano I; Vomero M; Berardicurti O; Pavlych V; Di Vico C; Caso F; Costa L; Tasso M; Camarda F; Misceo F; De Vincenzo F; Corrado A; Arcarese L; Rigon A; Vadacca M; Corberi E; Kun L; Trunfio F; Pilato A; Lamberti L; Cantatore FP; Perosa F; Guggino G; Scarpa R; Cipriani P; Ciccia F; Giacomelli R; Navarini L
    Arthritis Res Ther; 2024 Sep; 26(1):162. PubMed ID: 39294672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.